Search company, investor...

Chaperone Technologies


Unattributed VC | Alive

Total Raised


Last Raised

$100K | 17 yrs ago

About Chaperone Technologies

Chaperone Technologies, Inc. is developing antimicrobial products, based on a novel and proprietary mechanism of action, for difficult-to-treat and drug-resistant organisms across a broad range of infectious diseases. Chaperone's proven technology has already yielded the company's first product, a potent antimicrobial which is in development for treating complicated drug resistant Urinary Tract Infections.

Headquarters Location

1200 Liberty Ridge Drive Suite 310

Wayne, Pennsylvania, 19087,

United States


Missing: Chaperone Technologies's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Chaperone Technologies's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Chaperone Technologies Frequently Asked Questions (FAQ)

  • Where is Chaperone Technologies's headquarters?

    Chaperone Technologies's headquarters is located at 1200 Liberty Ridge Drive, Wayne.

  • What is Chaperone Technologies's latest funding round?

    Chaperone Technologies's latest funding round is Unattributed VC.

  • How much did Chaperone Technologies raise?

    Chaperone Technologies raised a total of $100K.

  • Who are the investors of Chaperone Technologies?

    Investors of Chaperone Technologies include Life Sciences Greenhouse of Central Pennsylvania.

  • Who are Chaperone Technologies's competitors?

    Competitors of Chaperone Technologies include Pfenex, Aphios, Hawaii Biotech, Array Biopharma, PDS Biotechnology and 12 more.

Compare Chaperone Technologies to Competitors

Zetra Biologicals

Zetra Biologicals is a preclinical stage biopharmaceutical company developing vaccines against pandemic influenza and other infectious diseases.

Nabi Biopharmaceuticals

has a broad product portfolio that modulates the immune system. Their research focuses on developing and commercializing novel vaccines and antibody-based therapies that prevent and treat infectious, autoimmune and addictive diseases, such as Staphylococcus aureus and hepatitis infections, and nicotine addiction.


SensiGen is a biotechnology company. They specialize creating tests to screen for diseases more efficiently and quickly. Their goal is to lower the overall costs of diagnosing serious diseases, usually ones where not many diagnostic tests exist.


AM-Pharma is a biopharmaceutical company that focuses on the development of recombinant Alkaline Phosphatase for clinical use.

Neugenesis Corporation

Neugenesis Corporation is focused on generating better biotherapeutics, cost-effectively. To this end, Neugenesis has developed technology for the discovery, improvement and production of complex proteins; especially heteromeric proteins. The Company's work with the filamentous fungi Neurospora crassa has resulted in significant advances in three important areas of biotechnology: directed evolution, combinatorial biology and recombinant protein expression.


TargAnox offers therapeutics to treat diseases resulting from oxidative stress-induced protein aging

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.